These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31023256)

  • 41. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.
    Eeckhoute J; Carroll JS; Geistlinger TR; Torres-Arzayus MI; Brown M
    Genes Dev; 2006 Sep; 20(18):2513-26. PubMed ID: 16980581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
    Sourvinos G; Spandidos DA
    Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of CCND1 +870A>G and VEGF +936C>T polymorphisms on oral cancer development and disease-free survival in a Taiwan population.
    Lin YC; Yeh CJ; Wang LH; Lee CW; Chen CH
    Oral Oncol; 2012 Jun; 48(6):535-40. PubMed ID: 22321253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
    Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer.
    Spyratos F; Andrieu C; Vidaud D; Briffod M; Vidaud M; Lidereau R; Bièche I
    Int J Biol Markers; 2000; 15(3):210-4. PubMed ID: 11012095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
    Yu CP; Yu JC; Sun CA; Tzao C; Ho JY; Yen AM
    Breast Cancer Res Treat; 2008 Jan; 107(1):95-102. PubMed ID: 18043898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.
    Justenhoven C; Pierl CB; Haas S; Fischer HP; Hamann U; Baisch C; Harth V; Spickenheuer A; Rabstein S; Vollmert C; Illig T; Pesch B; Brüning T; Dippon J; Ko YD; Brauch H
    Int J Cancer; 2009 May; 124(9):2077-81. PubMed ID: 19142864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma.
    Wang MT; Chen G; An SJ; Chen ZH; Huang ZM; Xiao P; Ben XS; Xie Z; Chen SL; Luo DL; Tang JM; Lin JY; Zhang XC; Wu YL
    Dis Esophagus; 2012; 25(7):664-70. PubMed ID: 22150974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
    Ho JY; Hsu RJ; Wu CL; Chen SH; Wu MY; Yu JC; Gao HW; Yen AM; Chen HH; Yu CP
    Eur J Cancer Prev; 2015 Sep; 24(5):407-15. PubMed ID: 25622084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
    Yang Q; Sakurai T; Mori I; Yoshimura G; Nakamura M; Nakamura Y; Suzuma T; Tamaki T; Umemura T; Kakudo K
    Cancer; 2001 Jul; 92(1):54-60. PubMed ID: 11443609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.
    Xu P; Zhao M; Liu Z; Liu Y; Chen Y; Luo R; Fang W
    Int J Clin Exp Pathol; 2015; 8(12):15887-94. PubMed ID: 26884860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    Ahmed F; Christos PJ; Singh P; Parashar B; Wernicke AG
    Am J Clin Oncol; 2019 May; 42(5):446-453. PubMed ID: 30973374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological significance of BRCA1 promoter hypermethylation in Thai breast cancer patients.
    Saelee P; Chaiwerawattana A; Ogawa K; Cho YM; Tiwawech D; Suktangman V
    Asian Pac J Cancer Prev; 2014; 15(24):10585-9. PubMed ID: 25605143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of the Ubiquitin-Specific Peptidase 9 X-Linked (USP9X) Gene is Associated with Upregulation of Cyclin D1 (CCND1) and Downregulation of Cyclin-Dependent Inhibitor Kinase 1A (CDKN1A) in Breast Cancer Tissue and Cell Lines.
    Li H; Zheng B
    Med Sci Monit; 2019 Jun; 25():4207-4216. PubMed ID: 31169265
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.
    Nakuci E; Mahner S; Direnzo J; ElShamy WM
    Exp Cell Res; 2006 Oct; 312(16):3120-31. PubMed ID: 16860316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
    Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.